[go: up one dir, main page]

CA3119071C - Formulations de nanoparticules lipidiques - Google Patents

Formulations de nanoparticules lipidiques

Info

Publication number
CA3119071C
CA3119071C CA3119071A CA3119071A CA3119071C CA 3119071 C CA3119071 C CA 3119071C CA 3119071 A CA3119071 A CA 3119071A CA 3119071 A CA3119071 A CA 3119071A CA 3119071 C CA3119071 C CA 3119071C
Authority
CA
Canada
Prior art keywords
nucleic acid
lipid
sirna
nucleotides
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3119071A
Other languages
English (en)
Other versions
CA3119071A1 (fr
Inventor
Adam Judge
James Heyes
Kieu Mong LAM
Lorne Ralph PALMER
Petra Schreiner
Original Assignee
Arbutus Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbutus Biopharma Corp filed Critical Arbutus Biopharma Corp
Priority claimed from PCT/US2019/060582 external-priority patent/WO2020097540A1/fr
Publication of CA3119071A1 publication Critical patent/CA3119071A1/fr
Application granted granted Critical
Publication of CA3119071C publication Critical patent/CA3119071C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne certaines nanoparticules lipidiques spécifiques comprenant : (a) une ou plusieurs molécules d'acide nucléique; (b) le cholestérol; (c) DSPC; (d) PEG-C-DMA; et (e) un lipide cationique; et des compositions pharmaceutiques comprenant les nanoparticules lipidiques. Les nanoparticules lipidiques et les compositions pharmaceutiques sont particulièrement utiles pour administrer un acide nucléique tel qu'un ARNsi ou un ARNm à un patient (par exemple un être humain) ou à une cellule.
CA3119071A 2018-11-09 2019-11-08 Formulations de nanoparticules lipidiques Active CA3119071C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862758088P 2018-11-09 2018-11-09
US62/758,088 2018-11-09
PCT/US2019/060582 WO2020097540A1 (fr) 2018-11-09 2019-11-08 Formulations de nanoparticules lipidiques

Publications (2)

Publication Number Publication Date
CA3119071A1 CA3119071A1 (fr) 2020-05-14
CA3119071C true CA3119071C (fr) 2026-01-13

Family

ID=

Similar Documents

Publication Publication Date Title
AU2019376161B2 (en) Lipid nanoparticle formulations
JP7506670B2 (ja) 脂質ナノ粒子製剤
EP4262883B1 (fr) Lipides peg et nanoparticules lipidiques
JP2022530018A (ja) 脂質ナノ粒子
JP2025019119A (ja) ケイ素を含有するカチオン性脂質
JP7709981B2 (ja) 肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質
JP2023534206A (ja) 肺に治療薬を送達するための脂質ナノ粒子
JP2023513698A (ja) 肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質
CA3119071C (fr) Formulations de nanoparticules lipidiques
EA046751B1 (ru) Липидная наночастица для доставки нуклеиновой кислоты пациенту или в клетку
HK40094731A (en) Peg lipids and lipid nanoparticles
HK40094731B (en) Peg lipids and lipid nanoparticles